Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 23Thoracic 15Breast 10Head & Neck 6Genitourinary 4Sarcoma 3Gynecologic 3Endocrine 3Tumor-Agnostic 2NET 2Dermatologic 2CNS 2Plasma cell 1Other solid neoplasm 1Lymphoid 1

Conditions

Sarcoma, Ewing 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm, Residual 1Gastrointestinal Stromal Tumors 1

Interventions

Radiotherapy 221Cyclophosphamide 211Doxorubicin 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 81Irinotecan 79pembrolizumab 75Radiation 70Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Surgical Procedures, Operative 57Peripheral Blood Stem Cell Transplantation 57Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liquid Biopsy × Sarcoma × Clear all
NCT06068075 2026-05-05

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Dana-Farber Cancer Institute

Phase NA Active not recruiting
340 enrolled
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive, Peripheral

NCT06515860 2026-01-09

NF1-TED

Boston Children's Hospital

Recruiting
1,000 enrolled
CNSSarcoma

Neurofibromatosis 1, Neurofibroma, Plexiform, Neurofibrosarcoma

NCT05408897 2022-09-21

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

Peking University People's Hospital

Recruiting
45 enrolled
GastrointestinalSarcoma

Neoplasm, Residual, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡